Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $15.7 million.

  • aTYR PHARMA's Total Current Liabilities rose 1104.97% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year increase of 1104.97%. This contributed to the annual value of $15.0 million for FY2024, which is 882.68% down from last year.
  • aTYR PHARMA's Total Current Liabilities amounted to $15.7 million in Q3 2025, which was up 1104.97% from $15.5 million recorded in Q2 2025.
  • aTYR PHARMA's Total Current Liabilities' 5-year high stood at $16.4 million during Q4 2023, with a 5-year trough of $4.5 million in Q1 2021.
  • Its 5-year average for Total Current Liabilities is $11.5 million, with a median of $12.4 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 5738.63% in 2021, then surged by 13053.38% in 2022.
  • Quarter analysis of 5 years shows aTYR PHARMA's Total Current Liabilities stood at $6.0 million in 2021, then surged by 130.53% to $13.9 million in 2022, then increased by 18.42% to $16.4 million in 2023, then decreased by 8.83% to $15.0 million in 2024, then increased by 4.75% to $15.7 million in 2025.
  • Its last three reported values are $15.7 million in Q3 2025, $15.5 million for Q2 2025, and $10.7 million during Q1 2025.